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Abstract 
Background 
Patients with cardiovascular (CV) disease have an increased circulating angiotensin-converting enzyme 2 (ACE2) 
activity, but there is little information about changes in ACE2 in chronic kidney disease (CKD) patients without 
history of CV disease. We examined circulating ACE2 activity in CKD patients at stages 3–5 (CKD3-5) and in 
dialysis (CKD5D) without any history of CV disease. 
Methods 
Circulating ACE2 activity was measured in human ethylenediamine-tetraacetic acid (EDTA)-plasma samples from 
the NEFRONA study (n = 2572): control group (CONT) (n = 568), CKD3-5 (n = 1458) and CKD5D (n = 546). 
Different clinical and analytical variables such as gender; age; history of diabetes mellitus (DM), dyslipidemia and 
hypertension; glycaemic, renal, lipid and anaemia profiles; vitamin D analogues treatment and antihypertensive 
treatments (angiotensin-converting enzyme inhibitor and angiotensin receptor blockade) were analysed. Circulating 
ACE2 and ACE activities were measured using modified fluorimetric assay for EDTA-plasma samples, where zinc 
chloride was added to recover enzymatic activity. 
Results 
In CKD3-5 and CKD5D, significant decrease in circulating ACE2 activity was observed when compared with 
CONT, but no differences were found between CKD3-5 and CKD5 when performing paired case-control studies. By 
multivariate linear regression analysis, male gender and advanced age were identified as independent predictors of 
ACE2 activity in all groups. Diabetes was identified as independent predictor of ACE2 activity in CKD3-5. 
Significant increase in the activity of circulating ACE was found in CKD3-5 and CKD5D when compared with 
CONT and in CKD5D when compared with CKD3-5. By multiple regression analysis, female gender and younger 
age were identified as independent predictors of ACE activity in CONT and CKD3-5. Diabetes was also identified as 
an independent predictor of ACE activity in CKD3-5 patients. 
Conclusions 
Circulating ACE2 and ACE activities can be measured in human EDTA-plasma samples with zinc added to recover 
enzymatic activity. In a CKD population without previous history of CV disease, ACE2 activity from human EDTA-
plasma samples directly correlated with the classical CV risk factors namely older age, diabetes and male gender. Our 
data suggest that circulating ACE2 is altered in CKD patients at risk for CV event. 
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INTRODUCTION 
Patients with chronic kidney disease (CKD) have an increased cardiovascular (CV) risk that accounts 
for more than 50% of the overall mortality [1]. Previous studies have found an independent association 
between lower levels of the estimated glomerular filtration rate (GFR) and the risk of CV disease (death, 
CV events and hospitalization). This risk is evident at an estimated GFR of <60 mL/min/1.73 m
2
 and 
increases with an estimated GFR of <45 mL/min/1.73 m
2
 [2]. The mechanisms that contribute to the 
pathogenesis of CV disease in CKD are complex and include both traditional and non-traditional CV risk 
factors [3]. Nonetheless, it is well known that enhanced activation of the renin–angiotensin system (RAS), 
among others, plays a major role in the progression of cardiac and renal injury [4]. 
 
Within the RAS, the angiotensin-converting enzyme (ACE) [5] converts angiotensin (Ang) I into the 
vasoconstrictor AngII, which mediates its effects predominantly through angiotensin type 1 receptor and 
is responsible for the pathophysiological effects of the RAS. AngII increases blood pressure and 
contributes to cardiac remodelling, fibrosis, inflammation, thrombosis and plaque rupture [6]. In 2000, 
ACE2, an enzyme that cleaves the C-terminal amino acid of AngII to generate the peptide Ang1-7, was 
identified [7]. Ang1-7 acts via the Mas receptor to counteract the adverse effects of AngII [8]. Previous 
experimental studies have reported that downregulation of ACE2 leads to age-dependent development of 
glomerular mesangial expansion, accelerated progression of glomerulosclerosis, tubular injury, 
macrophage infiltration and interstitial fibrosis [9–11]. 
 
ACE2 is an integral cell membrane protein that can undergo cleavage or shedding to release the 
catalytically active ectodomain into the circulation. Initial studies in a large cohort were able to detect 
circulating ACE2 activity in only 7.5% of the subjects, and it was ∼100-fold lower than ACE [12]. 
Interestingly, subjects with detectable ACE2 were older than those without and had a higher prevalence 
of CV disease, diabetes and hypertension suggesting that ACE2 may be upregulated in subjects with CV 
disease to counteract the adverse effect of AngII. Subsequent studies demonstrated that circulating ACE2 
activity could also be detected in healthy subjects [13] and that soluble ACE2 activity increases in heart 
failure patients, acute myocardial infarction [14], and correlates with the severity of the heart disease [15]. 
Circulating ACE2 levels increased in patients with type 1 diabetes and vascular complications [16]. Our 
group also demonstrated that circulating ACE2 activity can be measured in kidney transplant patients 
(KT), suggesting that it may be used as a non-invasive marker to understand the role of RAS in KT [17]. 
Recently, Roberts et al. showed that plasma ACE2 activity was lower in patients undergoing 
haemodialysis than in pre-dialysis patients with CKD [18]. However, circulating ACE2 activity has not 
been studied in CKD patients without previous history of CV events. Therefore, the aim of this study was 
to determine the levels of circulating ACE2 and ACE activities in CKD patients without any history of 
CV disease and to determine the factors associated with circulating ACE2 and ACE activities in this 
population. 
MATERIALS AND METHODS 
Patients and variables 
A total of 2572 subjects from an observational and multicentre study (NEFRONA project), recruited 
from October 2009 to June 2011, were studied [19, 20]. Male and female patients without history of CV 
disease (angina pectoris, acute myocardial infarction, ischaemic stroke, haemorrhagic stroke, abdominal 
aortic aneurysm and atherosclerosis) and in the age range between 18 and 74 years were included in the 
study. Exclusion criteria were pregnancy, human immunodeficiency virus infection, any type of 
transplantation or history of transplantation, previous history of carotid artery disease, patients with active 
infections and/or hospitalized in the last month, and intercurrent illness that presumes the absence of 
follow-up or survival expectation less than 1 year. 
  
Patients were classified into three groups according to their GFR [modification of diet in renal disease 
(MDRD)-4]: 1458 non-dialysis patients with CKD at stages 3–5 (CKD3-5, MDRD-4 <60 mL/min/1.73 
m
2
), 546 in dialysis (haemodialysis or peritoneal dialysis) patients (CKD5D) and 568 subjects with 
MDRD-4 ≥60 mL/min/1.73 m2 were used as controls (CONT). 
 
Clinical variables analysed were gender, age, history of diabetes, hypertension, dyslipidemia and 
smoking (active smokers over the last month). Angiotensin-converting enzyme inhibitor (ACEi), 
angiotensin receptor blockade (ARB), diabetes medication (insulin and oral antidiabetic drugs) and 
vitamin D analogues treatments were recorded. Analytical variables analysed were glycaemic (blood 
glucose and glycosylated haemoglobin), lipid and anaemia profiles. The presence of plaques was 
determined by ultrasound of the carotid arteries. 
 
Ethylenediamine-tetraacetic acid (EDTA)-anticoagulated plasma samples were collected from all 
patients and controls, centrifuged at 3000 g and then frozen at −80°C until analysis. The protocol has 
been reviewed and approved by the ethical review board of each hospital, and each participant signed an 
informed consent document before being included in the study. 
ACE2 enzymatic assay 
The ACE2 fluorescent enzymatic assay protocol was performed as previously described by our group, 
using an ACE2-quenched fluorescent substrate (Mca-Ala-Pro-Lys(Dnp)-OH, BioMol; Enzo, Life 
Sciences) [14, 17, 21]. Plasma samples were collected into tubes containing EDTA, a chelating agent of 
loosely bound metal ions such as Zn
2+
, which acts as a cofactor for carboxypeptidases. As EDTA inhibits 
ACE2 and ACE activities [22], zinc chloride (ZnCl2) was added to the plasma samples to avoid its 
bounding. Briefly, 2 µL of plasma was incubated with buffer (100 mM Tris-HCl, 600 mM NaCl, 10 µM 
ZnCl2, pH 7.5) in the presence of protease inhibitors (100 µM captopril, 5 µM amastatin, 5 µM bestatin 
and 10 µM Z-Pro-prolinal) and in the presence of different concentrations of ZnCl2 (0, 0.5, 1 and 3 mM) 
(Figure 1A). Samples were incubated with 20 µM of the quenched fluorescent substrate in reaction buffer 
(final volume 100 µL) at 37°C for 16 h. The optimal concentration of ZnCl2 for the determination of 
ACE2 activity was 0.5 mM. ACE2 activity was also calculated in heparin–plasma and serum samples 
from 21 subjects as previously described [14, 17]. We performed a standard curve of the recombinant 
human ACE2 (rhACE2, Calbiochem) adding increasing quantities of rhACE2 (0, 1, 2, 4, 8 and 16 ng) 
(Figure 1C). In a set of experiments, serum and EDTA-plasma samples were incubated with rhACE2 in 
the presence or absence of ZnCl2. Experiments were carried out in duplicate, and results were expressed 
as RFU/µL plasma/hour. 
  
 
 
 
FIGURE 1. Circulating ACE2 (A) and ACE (B) enzymatic activities at increased concentrations of zinc chloride (ZnCl2). (C) 
Standard curve of recombinant human ACE2 (rhACE2). (D) ACE2 activity in EDTA-plasma samples with the rhACE2 and ZnCl2. 
(A) ACE2 activity was assessed in six different EDTA-plasma samples (1–6) using the following concentrations of ZnCl2: 0, 0.5, 1 
and 3 mM. (B) ACE activity was assessed in four different EDTA-plasma samples (A–D) using the following concentrations of 
ZnCl2: 0, 7.81, 15.63 and 31.25 mM. (C) ACE2 activity was linearly increased with increasing the rhACE2 concentrations. (D) 
ACE2 activity was assessed in four EDTA-plasma samples with the following conditions: EDTA-plasma alone, EDTA-plasma 
adding ZnCl2 at a concentration of 0.5 mM, EDTA-plasma adding 1 ng of rhACE2 and EDTA-plasma adding both ZnCl2 at 0.5 mM 
and 1 ng of rhACE2. 
ACE enzymatic assay 
The ACE fluorescent enzymatic assay was performed as previously described with modifications [23]. 
ZnCl2 was tested to find the optimal concentration for reversing the effect of EDTA. Briefly, 0.83 µL of 
plasma with different concentrations of ZnCl2 (0, 7.81, 15.63 and 31.25 mM) (Figure 1B) was incubated 
with 73 µL of appropriate buffer [0.5 M borate buffer and 5.45 M N-hippuryl-His-Leu (HHL)] at 37°C 
for 25 min. Finally, the fluorescent adduct of the enzyme-catalysed product l-histidyl-l-leucine was 
quantified. A concentration of 15.63 mM was found to be optimal for the detection of ACE. ACE activity 
was also calculated in heparin-plasma and serum samples from 21 subjects as previously described [17]. 
Experiments were carried out in duplicate, and results were expressed as RFU/µL plasma. 
  
Statistical analysis 
Normality of continuous variables was assessed by normal probability plots. Variables were expressed 
as mean ± SE. Paired case-control studies were performed: CONT versus CKD3-5 (280 pairs), CONT 
versus CKD5D (188 pairs) and CKD3-5 versus CKD5D (360 pairs), with an equal distribution of gender, 
diabetes, hypertension, dyslipidemia, smoking habits, weight (±5 kg) and age (±3 years). Continuous 
variables were evaluated by the non-parametric Mann–Whitney test. Bivariate correlations were 
calculated by Spearman's correlation coefficient. ANOVA was used among plasma ACE2 and ACE 
activities. The intraclass correlation coefficient (ICC) was used to determine the concordance of the assay 
between the different human samples. Multiple linear regression analyses, using the natural logarithmic 
transformation of plasma ACE2 and ACE activities, were carried out to identify independent predictors of 
enzymatic activity. SPSS version 18.0 for Windows was used for statistical calculations and R package 
version 3.0.2 was used for case-control studies. P < 0.05 was considered statistically significant. 
RESULTS 
Patient characteristics 
In total, 2572 patients were included in the study. Circulating ACE2 and ACE activities were 
measured in 568 CONT subjects and 2004 CKD patients without previous history of CV disease, divided 
into those not requiring dialysis (CKD3-5) and those in dialysis (CKD5D). Characteristics of study 
subjects are shown in Table 1. CKD5D patients were younger and thinner than CKD3-5. CKD3-5 and 
CKD5D patients had higher prevalence of hypertension and dyslipidemia than CONT. NEFRONA is the 
first large study describing the actual prevalence of subclinical atheromatosis across different CKD 
stages. The baseline atherosclerosis parameters of the patients have been detailed by Arroyo et al. [24]. 
  
Table 1. Clinical characteristics of study cohorts 
 
P-value  
  
Total 
population  
CONT  CKD3-5  CKD5D  
CONT versus 
CKD3-5  
CONT versus 
CKD5D  
CKD3-5 versus 
CKD5D  
        
Age (years)  56.8 ± 12.65  54.3 ± 
11.49  
59.5 ± 
11.86  
52.86 ± 
13.77  
P < 0.001  P = 0.094  P < 0.001  
Male/female  1555/1017  347/272  1093/662  409/279  P = 0.020  P = 0.632  P = 0.593  
Diabetes  584 (22.7%)  76 
(12.3%)  
506 
(28.8%)  
124 
(18.0%)  
P < 0.001  P = 0.038  P < 0.001  
Hypertension  2006 (78%)  248 
(40.1%)  
1588 
(90.5%)  
590 
(85.8%)  
P < 0.001  P < 0.001  P = 0.009  
Dyslipidemia  1491 (58%)  231 
(37.3%)  
1215 
(69.2%)  
363 
(52.8%)  
P < 0.001  P < 0.001  P < 0.001  
Smoking  512 (19.9%)  128 
(20.7%)  
337 
(19.2%)  
138 
(20.1%)  
P = 0.149  P = 0.091  P = 1  
Body weight (kg)  76.4 ± 15.23  77.2 ± 
15.03  
78.0 ± 
14.85  
72.40 ± 
15.70  
P = 0.642  P < 0.001  P < 0.001  
Glycosylated 
haemoglobin (%)  
5.9 ± 1.19  5.7 ± 1.04  6.3 ± 1.30  5.51 ± 1.07  P < 0.001  P = 0.218  P < 0.001  
GFR (mL/min/1.73 
m2)  
48.3 ± 29.81  89.5 ± 
17.66  
32.6 ± 
13.86  
—  P < 0.001  —  —  
ACEi treatment  680 (26.4%)  64 
(10.3%)  
601 
(34.2%)  
130 
(18.9%)  
P < 0.001  P = 0.001  P < 0.001  
ARB treatment  1116 (43.4%)  145 
(23.4%)  
994 
(56.6%)  
219 
(31.8%)  
P < 0.001  P = 0.004  P < 0.001  
Insulin treatment  316 (12.3%)  11 (1.8%)  281 
(16.0%)  
219 
(31.8%)  
P < 0.001  P < 0.001  P = 0.400 
        
 
Continuous variables are expressed as means ± SD, and categorical variables are represented by the number and the percentage of 
patients. CONT, control patients; CKD3-5, non-dialysis patients with chronic kidney disease stage 3–5; CKD5D, dialysis patients; 
ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers. 
ACE2 and ACE activities in EDTA-plasma samples 
We studied ACE and ACE2 activities in EDTA-plasma samples. For this purpose, ACE and ACE2 
activities were measured in different conditions: EDTA-plasma samples, EDTA-plasma samples with 
added ZnCl2, and serum samples and plasma samples collected on heparin from 21 subjects. 
 
We found a strong correlation with ICC (≥0.84) between the different studied samples (plasma on 
EDTA+ZnCl2, heparin and serum) for both ACE2 and ACE activities. In addition, we were able to 
recover ≥91% of ACE2 activity and ≥83% of ACE activity from EDTA-plasma when ZnCl2 was added to 
the assays (Table 2). 
  
Table 2. ICCs and percentage of recovery for ACE2 and ACE activities between different sample conditions 
  
ICC  
(95% Confidence interval)  
ACE2 activity  ACE activity  
   
EDTA-plasma ZnCl2 sample versus serum sample  0.95  0.90  
(0.91–0.97)  (0.90–0.95)  
Serum sample versus plasma-heparin sample  0.95  0.93  
(0.91–0.98)  (0.86–0.97)  
EDTA-plasma ZnCl2 sample versus plasma-heparin sample  0.97  0.84  
(0.94–0.98)  (0.68–0.92)  
  
% Recovery  
   
EDTA-plasma ZnCl2 sample versus serum sample  107%  89%  
EDTA-plasma ZnCl2 sample versus plasma-heparin sample  91%  83%  
   
 
In concordance with the non-detectable ACE2 activity observed in EDTA-plasma samples, when 
rhACE2 was added to the EDTA-plasma, ACE2 activity was not observed (Figure 1D). As expected, 
when ZnCl2 was added to the EDTA-plasma with rhACE2, ACE2 activity was detected. These results 
demonstrated that within EDTA-plasma neither endogenous nor exogenous ACE2 activities were 
detected; however, the addition of zinc to the reaction was able to recover the enzymatic activity. 
ACE2 activity 
Circulating ACE2 activity significantly decreased in CKD3-5 as compared with CONT (45.4 ± 1.12 
versus 52.9 ± 1.50, P < 0.001) and in CKD5D as compared with CONT (38.5 ± 1.62 versus 52.9 ± 1.50, P 
< 0.001). In addition, ACE2 significantly decreased in CKD5D as compared with CKD3-5 (38.5 ± 1.62 
versus 45.4 ± 1.12, P < 0.001) (Figure 2A). However, when paired case-control studies were performed, 
no differences between CKD3-5 and CKD5D were found (P = 0.27) (Figure 2B). Therefore, we analysed 
all groups separately. 
  
 
 
 
FIGURE 2. Circulating ACE2 activity between studied groups. (A) ACE2 activity significantly decreased in CKD3-5 (grey bars) 
and CKD5D (white bars) patients as compared with CONT (black bars) (*P < 0.001). CKD3-5 showed an increase in plasma ACE2 
activity as compared with CKD5D ($P < 0.001). When matching samples with an equal distribution of gender, diabetes, 
hypertension, dyslipidemia, smoking habits, weight and age (B), ACE2 activity significantly decreased in CKD3-5 and CKD5D as 
compared with CONT, but no differences were found between CKD3-5 and CKD5D (P = 0.27). CONT, control patients; CKD3-5, 
non-dialysis patients with chronic kidney disease stage 3–5; CKD5D, dialysis. 
Males had significantly increased ACE2 activity when compared with females in all studied groups (P 
< 0.001). Furthermore, patients with plaques also had increased ACE2 activity as compared with those 
without plaques (P < 0.001) (Table 3). 
  
Table 3. Influence of different variables and treatments on circulating ACE2 and ACE activities in each studied group 
  
Circulating ACE2 activity (RFU/µL/h) ± SEM   Circulating ACE activity (RFU/µL) ± SEM 
Clinical variables  
CONT  CKD3-5  CKD5D   CONT  CKD3-5  CKD5D  
 
Gender  
 Male  61.4 ± 2.26  50.6 ± 1.53  45.6 ± 2.45   3541.2 ± 94.8  4032.8 ± 71.8  4574.9 ± 109.9  
 Female  42.5 ± 1.61*  36.7 ± 1.47*  27.7 ± 1.37*   4144.1 ± 106.9*  4426.9 ± 98.6*  4270.0 ± 141.8  
Diabetes  
 No  51.8 ± 1.59  43.4 ± 1.35  37.1 ± 1.43   3766.5 ± 75.4  4103.5 ± 66.7  4459.7 ± 97.2  
 Yes  62.0 ± 4.30*  50.3 ± 1.97*  45.0 ± 6.06   4127.7 ± 230.3  4378.0 ± 117.7  4431.1 ± 196.3  
Hypertension  
 No  47.2 ± 1.30  43.2 ± 2.87  36.7 ± 4.05   3825.9 ± 89.6  4669.2 ± 189.6  14666.3 ± 188.5  
 Yes  62.0 ± 3.18*  45.6 ± 1.20  38.8 ± 1.76   3782.5 ± 120.5  4130.8 ± 61.2*  4418.1 ± 96.8  
Dyslipidemia  
 No  49.5 ± 1.61  43.6 ± 1.55  33.9 ± 1.30   3806.3 ± 90.0  4404.8 ± 105.8  4369.9 ± 118.1  
 Yes  59.0 ± 2.97*  46.2 ± 1.47  42.7 ± 2.83*   3814.1 ± 120.1  4080.2 ± 69.8*  4531.4 ± 127.0  
Smoking  
 No  51.7 ± 1.49  44.5 ± 1.19  38.0 ± 1.74   3817.8 ± 80.7  4229.4 ± 65.2  4414.2 ± 94.4  
 Yes  57.8 ± 4.40  49.4 ± 2.96*  40.5 ± 4.02   3775.8 ± 159.7  3976.7 ± 130.5  4599.4 ± 212.3  
Plaques  
 Absence  48.9 ± 2.29  39.7 ± 1.89  31.2 ± 1.70   3995.0 ± 106.0  4159.6 ± 99.9  4310.2 ± 157.8  
 Presence  56.7 ± 1.94*  48.0 ± 1.38*  41.8 ± 2.19*   3638.5 ± 97.0*  4191.7 ± 71.8  4518.1 ± 104.4  
  Treatments  
ACEi  
 No  52.5 ± 1.59  46.2 ± 1.48  38.9 ± 1.92   3908.4 ± 75.5  4993.8 ± 70.3  4945.9 ± 87.5  
 Yes  57.4 ± 4.33  44.0 ± 1.65  37.2 ± 2.38   2889.8 ± 203.0*  2694.7 ± 64.6*  2410.6 ± 145.4*  
ARB  
 No  49.7 ± 1.27  43.7 ± 1.49  37.7 ± 2.17   3719.6 ± 80.3  3729.7 ± 85.2  4367.3 ± 102.4  
 Yes  64.2 ± 4.89*  46.7 ± 1.62  40.3 ± 1.99*   4116.3 ± 158.3*  4535.1 ± 77.8*  4647.1 ± 163.8  
Oral antidiabetic drugs  
 No  51.9 ± 1.51  44.2 ± 1.19  38.6 ± 1.64   3795.0 ± 75.2  4165.4 ± 61.9  4464.7 ± 88.1  
 Yes  63.1 ± 4.89*  54.6 ± 3.31*  35.1 ± 5.86   3937.7 ± 245.2  4307.7 ± 175.2  3954.3 ± 582.9  
Insulin  
 No  52.9 ± 1.5  44.7 ± 1.26  37.3 ± 1.49   3805.3 ± 72.1  4112.8 ± 61.6  4470.8 ± 94.4  
 Yes  59.6 ± 11.85  48.9 ± 2.17*  45.5 ± 6.84   4087.1 ± 848.3  4549.9 ± 168.3  4356.9 ± 227.5  
Cholecalciferol  
 No  53.0 ± 1.50  45.6 ± 1.15  39.0 ± 1.66   3805.0 ± 72.0  4214.4 ± 59.7  4492.7 ± 88.3  
 Yes  56.9 ± 0.00  37.9 ± 4.51  25.0 ± 3.94*   6215.3 ± 0.00  3211.4 ± 229.2*  3250.6 ± 438.7*  
        
 
CONT, control patients; CKD3-5, non-dialysis patients with chronic kidney disease stage 3–5; CKD5D, dialysis patients; ACEi, 
angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers. 
*P < 0.05 (no versus yes, male versus female and absence versus presence). 
 
 
  
CONT and CKD3-5 with diabetes showed increased circulating ACE2 activity as compared with non-
diabetic patients (P = 0.003 and P < 0.001). However, no differences were observed in dialysis patients (P 
= 0.60). Hypertension was also associated with increased ACE2 activity in CONT (P < 0.001) (Table 3). 
Patients with dyslipidemia showed increased levels of circulating ACE2 in CONT (P < 0.001) and 
CKD5D (P = 0.028), but no differences were found in CKD3-5 (P = 0.53). Interestingly, smokers had 
significantly increased circulating ACE2 activity as compared with non-smoker CKD3-5 (P = 0.03) 
(Table 3). 
 
We found a significant direct correlation between ACE2, age and glycosylated haemoglobin in both 
CONT (P < 0.001) and CKD3-5 (P < 0.05). In addition, a direct correlation between ACE2 and age was 
found in CKD5D (P = 0.038). 
 
Circulating ACE2 activity significantly increased in CONT and CKD5D on ARBs therapy as 
compared with non-treated patients (P = 0.002). Treatment with ACEi had no influence on circulating 
ACE2 (Table 3). ACE2 activity also increased in CONT (P = 0.007) and CKD3-5 (P < 0.001) under oral 
antidiabetic agents as compared with non-treated. In addition, insulin therapy increased ACE2 activity in 
CKD3-5 (P < 0.001) (Table 3). Surprisingly, circulating ACE2 decreased in CKD5D treated with 
cholecalciferol as compared with non-treated patients (P = 0.027) (Table 3). 
 
By multivariate linear regression analysis (Table 4), male gender and advanced age were identified as 
independent predictors of circulating ACE2 activity in all studied groups. Diabetes was also identified as 
independent predictor of ACE2 activity in CKD3-5. In addition, ARBs and cholecalciferol therapies were 
independent predictors of ACE2 in CKD5D. 
  
Table 4. Multiple linear regression analysis of potential predictors of circulating ACE2 
and ACE activities 
 
Standardized coefficient (β)  P-value  
Predictors of circulating ACE2 activity  
(a) CONT  
 Male  0.243  <0.001  
 Advanced age  0.148  <0.001  
(b) CKD3-5  
 Male  0.224  <0.001  
 Advanced age  0.060  0.020  
 Diabetes  0.074  0.004  
(c) CKD5D  
 Male  0.318  <0.001  
 Advanced age  0.119  0.003  
 ARB treatment  0.095  0.020  
 Cholecalciferol treatment  −0.095  0.018  
Predictors of circulating ACE Activity  
(a) CONT  
 Male  −0.182  <0.001  
 Advanced age  −0.087  0.035  
 ACEi treatment  −0.152  <0.001  
 ARB treatment  0.124  0.003  
(b) CKD3-5  
 Male  −0.062  0.004  
 Advanced age  −0.069  0.001  
 Diabetes  0.071  0.001  
 ACEi treatment  −0.562  <0.001  
 Cholecalciferol treatment  −0.074  0.001  
(c) CKD5D  
 ACEi treatment  −0.580  <0.001  
 Cholecalciferol treatment  −0.087  0.012  
   
 
Data are expressed as regression coefficients and P-value. Dependent variables: circulating ACE2 activity (expressed in LnACE2) 
and circulating ACE activity (expressed in LnACE). 
CONT, control patients; CKD3-5, non-dialysis patients with chronic kidney disease stage 3–5; CKD5D, dialysis patients; ACEi, 
angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers. 
ACE activity 
Circulating ACE activity significantly increased in CKD3-5 as compared with CONT (4181.65 ± 
58.37 versus 3809.13 ± 71.96, P = 0.035) and in CKD5D as compared with CONT (4454.48 ± 87.10 
versus 3809.13 ± 71.96, P < 0.001). In addition, ACE activity significantly increased in CKD5D as 
compared with CKD3-5 (4454.48 ± 87.10 versus 4181.65 ± 58.37, P = 0.001) (Figure 3A). In 
concordance, when paired case-control studies were performed, the same results were observed 
(Figure 3B). 
  
 
 
 
FIGURE 3. Circulating ACE activity between studied groups. (A) ACE activity was increased in CKD3-5 (grey bars) (*P = 0.035) 
and in CKD5D (white bars) (*<0.001) as compared with CONT (black bars). CKD5D showed an increase in plasma ACE activity 
as compared with CKD3-5 ($P = 0.001). When assessing a paired case-control study (B), same results were obtained. CONT, control 
patients; CKD3-5, non-dialysis patients with chronic kidney disease stage 3–5; CKD5D, dialysis. 
Females had increased circulating ACE activity as compared with males in CONT and CKD3-5 (P < 
0.001). However, no differences were observed in CKD5D (P = 0.057) (Table 3). 
 
CONT with the presence of plaques showed decreased levels of circulating ACE activity as compared 
with those without plaques (P = 0.011). However, no differences were observed in CKD3-5 and CKD5D. 
ACE activity decreased in CKD3-5 with hypertension or dyslipidemia as compared with non-
hypertensive (P = 0.001) or without dyslipidemia (P = 0.004) (Table 3). We found a significant indirect 
correlation between circulating ACE activity, age (P = 0.033) and glycosylated haemoglobin (P = 0.019) 
in CONT. 
 
Increased ACE activity was found in CONT and CKD3-5 in ARBs therapy as compared with non-
treated patients. As expected, subjects treated with ACEi had lower levels of ACE activity as compared 
with non-treated subjects in all groups. ACE activity decreased in CKD3-5 and CKD5D treated with 
cholecalciferol as compared with non-treated (Table 3). 
 
By multiple regression analysis (Table 4), female gender and younger age were identified as 
independent predictors of circulating ACE activity in CONT and CKD3-5. Diabetes was also identified as 
an independent predictor of circulating ACE activity in CKD3-5. As well as in the bivariate analysis, 
ACEi therapy was inversely associated with ACE activity in all studied groups. Furthermore, 
cholecalciferol treatment was found as an independent predictor of ACE activity in CKD3-5 and CKD5D. 
ARBs therapy was identified as an independent predictor of circulating ACE activity in CONT. 
  
DISCUSSION 
The present study demonstrates that circulating ACE2 and ACE activities may be measured in human 
EDTA-plasma. This is the first study showing that circulating ACE2 activity decreased in CKD3-5 and 
dialysis patients without previous history of CV disease. In addition, we also showed that ACE2 
correlates with the classical CV risk factors namely male gender, advanced age and diabetes in CKD3-5, 
and male gender and advanced age in CKD5D. 
 
ACE2 enzymatic activity has been widely studied in renal, heart and other tissues under physiological 
and pathological conditions [21, 22]. However, few studies have assessed human circulating ACE2 
activity, and the majority of them measured ACE2 activity in serum or heparin blood samples [12, 13]. 
We previously measured circulating ACE2 activity in serum from KT and acute myocardial infarction 
patients [14, 17]. Initially, we were not able to measure ACE2 activity in EDTA-plasma samples. The 
chelating agent EDTA completely inhibits tissue ACE2 and soluble secreted ACE2 from chinese hamster 
ovary cell media activity, by chelating the zinc ion required for the metalloprotease activity [22, 25]. 
Hence, we made an effort to measure ACE2 activity in EDTA-plasma samples. We demonstrated by 
adding zinc chloride and subsequently avoiding the EDTA chelating effect that ACE2 and ACE activities 
could be measured. 
 
Roberts et al. [18] demonstrated that plasma ACE2 activity decreased in dialysis patients. In those 
patients, male gender and diabetes were associated with increased ACE2, while RAS blockade did not 
affect circulating ACE2. However, in their study, the sample size was small and healthy subjects used for 
comparison were not contemporaneous with CKD patients. Here, we present a study with larger sample 
size (n = 2572) and contemporaneous study groups. Note that in our study, patients had no history of CV 
disease. In agreement with Roberts et al., we initially found circulating ACE2 activity decreased in 
dialysis patients. As expected, measurement of circulating ACE2 pre- and post-dialysis showed no 
differences (data not shown), demonstrating that the enzyme is not removed by dialysis. One surmises 
that the haemodialysis itself could not alter the levels of the ACE2 activity in plasma owing to its large 
molecular size [26]. In our study, dialysis patients were younger than CKD3-5 and control groups. When 
paired case-control studies were performed, the differences among the CKD groups were not observed, 
suggesting that the decrease in ACE2 within the dialysis patients may be ascribed to age. Within CKD5D, 
CKD3-5 and CONT, a significant difference in the level of circulating ACE2 activity was demonstrated 
between males and females. Our results confirm the work of others, who showed that circulating ACE2 is 
sex dependent, with higher levels in males [16–18]. Data from animal models suggest that soluble ACE2 
shedding is stimulated by the tumour necrosis factor-α convertase ADAM17 [27–29]. It is possible that 
the increase in ACE2 in males may be related to the increase in ADAM17 shedding. Further studies 
focused on the ADAM17/ACE2 axis and gender differences are needed to confirm this premise. 
 
Many studies have associated circulating ACE2 activity with higher risk of CV disease. Epelman et 
al. [15] have previously demonstrated that circulating ACE2 activity is elevated in patients with diagnosis 
of heart failure. In recent studies from our group, we showed that ACE2 activity is up-regulated in the 
acute phase of ST-elevation myocardial infarction and correlates with the infarct size [14]. Furthermore, 
KT patients with a previous history of ischaemic heart disease presented increased ACE2 activity [17]. 
Soro-Paavonen et al. demonstrated that circulating ACE2 increased in patients with diabetes and 
decreased eGFR or other vascular complications such as CV disease [16]. In concordance, in our study, 
we demonstrated that ACE2 activity also increases in diabetic CKD patients and it correlates with 
glycosylated haemoglobin. In mice with experimental diabetes, ACE2 activity increased in the renal 
cortex and in the circulation, suggesting a potential mechanism to adapt to diabetes-associated AngII 
overactivity [21, 22]. As circulating ACE2 activity increase starts at an early stage of diabetes and 
correlates with GFR, the measurement of ACE2 activity may become a new biomarker of CV disease in 
CKD. 
  
Circulating ACE activity increased in CKD3-5 and CKD5D without previous history of CV disease. 
We have demonstrated that ACE activity correlates with the classical CV risk factors such as male, 
advanced age and diabetes in CKD3-5. As expected, ACEi therapy was inversely associated with ACE 
activity in all groups. In concordance with our results, some studies have found lower levels of circulating 
ACE in subjects with a history of hypertension [12] and higher levels in diabetic patients with renal 
complications [30]. However, other studies have not found a relationship between circulating ACE and 
the classical CV risk factors [17, 31, 32]. We surmise that the incongruences observed between studies 
and populations may be ascribed to the effect of RAS blockade on circulating ACE. For ethical reasons, 
RAS blockade agents were not stopped for the study. 
 
In conclusion, this study shows that circulating ACE2 and ACE activities can be recovered and 
detected in human EDTA-plasma samples by adding zinc chloride. In addition, ACE2 activity directly 
correlated with the classical CV risk factors such as male gender, diabetes and older age. These findings 
may have therapeutic implications for CV disease and help to delay the progression of CKD. Prospective 
studies with a short- and long-term follow-up will help us to elucidate the ACE2 role as a biomarker in 
CKD. 
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